Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase.
adverse event following immunization
drug–vaccine interaction
immune checkpoint inhibitors
influenza vaccine
myocarditis
pericarditis
pharmacovigilance
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
received:
04
12
2020
revised:
23
12
2020
accepted:
28
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Evidence on whether the influenza vaccine could exacerbate immune-related adverse events, including myopericarditis (MP), in patients treated with immune checkpoint inhibitors (ICIs), is still conflicting. We explored this issue through a global real-world approach. We queried the Vaccine Adverse Event Reporting System (VAERS) and VigiBase to retrieve cases of MP in which the influenza vaccine and ICIs were recorded as suspect and were concomitantly reported. For the included cases, causality assessment and Drug Interaction Probability Scale (DIPS) algorithms were applied. There were 191 and 399 reports of MP with the influenza vaccine that were retrieved (VAERS and VigiBase, respectively). No case of MP reporting the concomitant use of ICIs and the influenza vaccine was found in VAERS, while three cases of myocarditis were retrieved in VigiBase. All of the cases were unclassifiable for a causality assessment because of the lack of data concerning latency. According to the DIPS, one report was categorized as possible and two as doubtful. The paucity of cases coupled with the doubtful causality assessment make the potential interaction between influenza vaccines and ICIs in cancer patients negligible from clinical and epidemiological standpoints. These findings support the cardiovascular safety of the influenza vaccination, which remains strongly recommended in cancer patients, especially in the current COVID-19 era.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence on whether the influenza vaccine could exacerbate immune-related adverse events, including myopericarditis (MP), in patients treated with immune checkpoint inhibitors (ICIs), is still conflicting. We explored this issue through a global real-world approach.
METHODS
METHODS
We queried the Vaccine Adverse Event Reporting System (VAERS) and VigiBase to retrieve cases of MP in which the influenza vaccine and ICIs were recorded as suspect and were concomitantly reported. For the included cases, causality assessment and Drug Interaction Probability Scale (DIPS) algorithms were applied.
RESULTS
RESULTS
There were 191 and 399 reports of MP with the influenza vaccine that were retrieved (VAERS and VigiBase, respectively). No case of MP reporting the concomitant use of ICIs and the influenza vaccine was found in VAERS, while three cases of myocarditis were retrieved in VigiBase. All of the cases were unclassifiable for a causality assessment because of the lack of data concerning latency. According to the DIPS, one report was categorized as possible and two as doubtful.
CONCLUSION
CONCLUSIONS
The paucity of cases coupled with the doubtful causality assessment make the potential interaction between influenza vaccines and ICIs in cancer patients negligible from clinical and epidemiological standpoints. These findings support the cardiovascular safety of the influenza vaccination, which remains strongly recommended in cancer patients, especially in the current COVID-19 era.
Identifiants
pubmed: 33406694
pii: vaccines9010019
doi: 10.3390/vaccines9010019
pmc: PMC7823897
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
Drug Saf. 2015 Sep;38(9):781-7
pubmed: 26239715
Int J Cardiol. 2018 Dec 15;273:183-186
pubmed: 30236504
Expert Rev Vaccines. 2018 Apr;17(4):363-381
pubmed: 29452497
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
BMC Public Health. 2008 Aug 01;8:272
pubmed: 18673545
Ann Pharmacother. 2007 Apr;41(4):674-80
pubmed: 17389673
J Oncol Pharm Pract. 2020 Apr;26(3):647-654
pubmed: 31474214
J Oncol Pharm Pract. 2019 Apr;25(3):663-673
pubmed: 29996738
Int J Cardiol. 2008 Nov 28;130(3):304-9
pubmed: 18625525
Vaccine. 1999 Jul 16;17(22):2908-17
pubmed: 10438063
JCO Oncol Pract. 2020 Jul;16(7):e573-e580
pubmed: 32048920
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
J Clin Neuromuscul Dis. 2019 Jun;20(4):194-199
pubmed: 31135622
Vaccine. 2015 Aug 26;33(36):4398-405
pubmed: 26209838
J Clin Pathol. 2009 Dec;62(12):1074-84
pubmed: 19946094
Int J Environ Res Public Health. 2020 Oct 27;17(21):
pubmed: 33121070
Acta Diabetol. 2020 Jan;57(1):71-80
pubmed: 31203438
BMC Pharmacol Toxicol. 2018 May 5;19(1):20
pubmed: 29728118
Lancet. 2018 Aug 4;392(10145):383
pubmed: 30102168
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
Infection. 2007 Oct;35(5):308-19
pubmed: 17885730
J Clin Neuromuscul Dis. 2017 Dec;19(2):80-83
pubmed: 29189553
JAMA. 2013 Oct 23;310(16):1711-20
pubmed: 24150467
N Engl J Med. 2018 Mar 22;378(12):1165
pubmed: 29562154
Target Oncol. 2020 Aug;15(4):449-466
pubmed: 32725437
J Immunother Cancer. 2019 Feb 22;7(1):53
pubmed: 30795818
Immunotherapy. 2020 Feb;12(2):151-159
pubmed: 32089035
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Cancer. 2005 Aug 1;104(3):618-28
pubmed: 15973737
Vaccine. 2015 Jul 17;33(31):3773-8
pubmed: 25999283
Vaccine. 2015 Mar 30;33(14):1682-7
pubmed: 25720791
Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983
pubmed: 29388675
Int J Infect Dis. 2020 Oct;99:393-396
pubmed: 32768696
Immunotherapy. 2020 Oct;12(15):1139-1148
pubmed: 32933369
Clin Nutr. 2020 Jul 29;:
pubmed: 32778460
Crit Rev Oncol Hematol. 2019 Jul;139:87-90
pubmed: 31112887
Eur J Cancer. 2018 Nov;104:182-187
pubmed: 30368069
Lancet. 2000 Oct 7;356(9237):1255-9
pubmed: 11072960
J Immunother Cancer. 2018 May 22;6(1):40
pubmed: 29789020
Clin Infect Dis. 2020 Jan 2;70(2):193-199
pubmed: 30874791